Fluorouracil/Irinotecan/Leucovorin Calcium regimen (IFL)

Known as: IFL, Saltz Regimen, 5FU/Leucovorin/Irinotecan 
A combination of agents containing fluorouracil, irinotecan and leucovorin calcium.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
PURPOSE Colon cancers exhibiting DNA mismatch repair (MMR) defects demonstrate distinct clinical and pathologic features… (More)
Is this relevant?
2007
2007
PURPOSE Panitumumab is a fully human monoclonal antibody directed against the epidermal growth factor receptor and is indicated… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE Previously, we reported results of Intergroup N9741, which compared standard bolus fluorouracil (FU), leucovorin, plus… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE Bevacizumab is a monoclonal antibody to vascular endothelial growth factor-A (VEGF). In the pivotal trial in metastatic… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE In a phase III trial, combining bevacizumab (BV)--a recombinant, humanized, monoclonal antibody targeting vascular… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA), a recombinant, humanized anti-vascular endothelial growth… (More)
Is this relevant?
Review
2005
Review
2005
Combination chemotherapy regimens including irinotecan and oxaliplatin markedly improve response rate and prolong median survival… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
PURPOSE Three agents with differing mechanisms of action are available for treatment of advanced colorectal cancer: fluorouracil… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE In North America, no effective therapy has been available for patients with progressive metastatic colorectal cancer… (More)
Is this relevant?